OBJECTIVE: Diabetes frequently complicates cystic fibrosis (CF) without fasting hyperglycemia or despite spontaneous hypoglycemia (anecdotally ascribed to malnutrition), whose prevalence, clinical meaning, and relationship with glucose tolerance and clinical/nutritional status were not previously investigated. The relationship of CF genotype with insulin secretion control is also unclear. DESIGN AND METHODS: A total of 129 CF patients without stable diabetes received 188 oral glucose tolerance tests. Distribution of fasting plasma glucose (FPG), glucose, insulin and C-peptide responses, clinical/nutritional variables, and their relationships were analyzed. RESULTS: FPG < 60 mg/dl (3.3 mmo/l) was detected in 14% of studies and reactive hypoglycemia (PG < 50 mg/dl (2.8 mmo/l)) in 15%. OGTT-based diabetes frequency was similar in the lowest quartile (Q1) and Q2-3 for FPG (10 and 8%), with higher glucose increment and area under the curve in Q1. Insulin and C-peptide levels were similar among FPG quartiles. Class I cystic fibrosis transmembrane conductance regulator mutation carriers had higher insulin concentrations than class II, especially in Q1 for FPG. Age, sex, nutritional, and anthropometric parameters including fat and lean body mass were unrelated to FPG. Lower FPG was associated with more frequent hospitalization rates (P = 0.002) and lower Shwachman scores (P = 0.041). Steroids weaning was accurately evaluated but then excluded as a possible cause of hypoglycemia. CONCLUSIONS/ INTERPRETATION: Fasting asymptomatic hypoglycemia is frequent and possibly related to inappropriate insulin secretion control in class I mutation carriers. Low FPG does not exclude impaired glucose tolerance (IGT) and diabetes in CF and reflects worse clinical status.
OBJECTIVE:Diabetes frequently complicates cystic fibrosis (CF) without fasting hyperglycemia or despite spontaneous hypoglycemia (anecdotally ascribed to malnutrition), whose prevalence, clinical meaning, and relationship with glucose tolerance and clinical/nutritional status were not previously investigated. The relationship of CF genotype with insulin secretion control is also unclear. DESIGN AND METHODS: A total of 129 CFpatients without stable diabetes received 188 oral glucose tolerance tests. Distribution of fasting plasma glucose (FPG), glucose, insulin and C-peptide responses, clinical/nutritional variables, and their relationships were analyzed. RESULTS: FPG < 60 mg/dl (3.3 mmo/l) was detected in 14% of studies and reactive hypoglycemia (PG < 50 mg/dl (2.8 mmo/l)) in 15%. OGTT-based diabetes frequency was similar in the lowest quartile (Q1) and Q2-3 for FPG (10 and 8%), with higher glucose increment and area under the curve in Q1. Insulin and C-peptide levels were similar among FPG quartiles. Class I cystic fibrosis transmembrane conductance regulator mutation carriers had higher insulin concentrations than class II, especially in Q1 for FPG. Age, sex, nutritional, and anthropometric parameters including fat and lean body mass were unrelated to FPG. Lower FPG was associated with more frequent hospitalization rates (P = 0.002) and lower Shwachman scores (P = 0.041). Steroids weaning was accurately evaluated but then excluded as a possible cause of hypoglycemia. CONCLUSIONS/ INTERPRETATION: Fasting asymptomatic hypoglycemia is frequent and possibly related to inappropriate insulin secretion control in class I mutation carriers. Low FPG does not exclude impaired glucose tolerance (IGT) and diabetes in CF and reflects worse clinical status.
Authors: Marissa J Kilberg; Clea Harris; Saba Sheikh; Darko Stefanovski; Marina Cuchel; Christina Kubrak; Denis Hadjiliadis; Ronald C Rubenstein; Michael R Rickels; Andrea Kelly Journal: J Clin Endocrinol Metab Date: 2020-10-01 Impact factor: 5.958
Authors: Marissa J Kilberg; Saba Sheikh; Darko Stefanovski; Christina Kubrak; Diva D De Leon; Denis Hadjiliadis; Ronald C Rubenstein; Michael R Rickels; Andrea Kelly Journal: J Cyst Fibros Date: 2019-08-08 Impact factor: 5.482
Authors: Alicia K Olivier; Yaling Yi; Xingshen Sun; Hongshu Sui; Bo Liang; Shanming Hu; Weiliang Xie; John T Fisher; Nicholas W Keiser; Diana Lei; Weihong Zhou; Ziying Yan; Guiying Li; Turan I A Evans; David K Meyerholz; Kai Wang; Zoe A Stewart; Andrew W Norris; John F Engelhardt Journal: J Clin Invest Date: 2012-09-17 Impact factor: 14.808
Authors: Moira L Aitken; Magdalena A Szkudlinska; Edward J Boyko; Debbie Ng; Kristina M Utzschneider; Steven E Kahn Journal: Diabetologia Date: 2020-01-29 Impact factor: 10.122
Authors: Christine L Chan; Timothy Vigers; Laura Pyle; Philip S Zeitler; Scott D Sagel; Kristen J Nadeau Journal: J Cyst Fibros Date: 2018-03-23 Impact factor: 5.482
Authors: Antoinette Moran; Carol Brunzell; Richard C Cohen; Marcia Katz; Bruce C Marshall; Gary Onady; Karen A Robinson; Kathryn A Sabadosa; Arlene Stecenko; Bonnie Slovis Journal: Diabetes Care Date: 2010-12 Impact factor: 19.112
Authors: Hongshu Sui; Yaling Yi; Jianrong Yao; Bo Liang; Xingshen Sun; Shanming Hu; Aliye Uc; Deborah J Nelson; Katie Larson Ode; Louis H Philipson; John F Engelhardt; Andrew W Norris Journal: PLoS One Date: 2014-03-03 Impact factor: 3.240